1,25-Dihydroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage

Cancer Research

Volumn 59, Issue 4, 1999, Pages 862-867

  Ravid, Amiram ^a   Rocker, Dafna ^a   Machlenkin, Arthur ^c   Rotem, Carmela ^c   Hochman, Ayala ^b   Kessler Icekson, Gania ^a   Liberman, Uri A ^a   Koren, Ruth ^a  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

1,4 BENZOQUINONE; ACETYLCYSTEINE; ANTIOXIDANT; CALCITRIOL; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; MENADIONE; MESSENGER RNA; REACTIVE OXYGEN METABOLITE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL COUNT; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CALCITRIOL; DNA TOPOISOMERASES, TYPE II; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG SYNERGISM; ETOPOSIDE; FEMALE; HUMANS; REACTIVE OXYGEN SPECIES; SUPEROXIDE DISMUTASE; TUMOR CELLS, CULTURED; VITAMIN K;

EID: 0033557922     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Studzinski, G. P., and Moore, D. C. Sunlight - can it prevent as well as cause cancer? Cancer Res., 55: 4014-4022, 1995.
2. Welsh, J. Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens. Biochem. Cell Biol., 72: 537-545, 1994.
3. 3 on mouse peritoneal macrophage functions. J. Immunol., 143: 3686-3690, 1989.
4. 3 increases cytotoxicity and exocytosis in lymphokine-activated killer cells. Mol. Cell. Endocrinol., 96: 133-139, 1993.
5. 3 potentiates the cytotoxic effect of TNF on human breast cancer cells. Mol. Cell. Endocrinol., 106: 157-162, 1994.
6. 3 increases the sensitivity of human renal carcinoma cells to tumor necrosis factor a but not to interferon a or lymphokine-activated-killer cells. J. Endocrinol., 149: 327-333, 1996.
7. 3 and agents that increase intracellular cAMP synergistically inhibit fibroblast proliferation. In Vitro Cell. Dev. Biol. Anim., 33: 310-314, 1997.
8. 3 and agents that increase intracellular cAMP synergistically inhibit fibroblast proliferation. In Vitro Cell. Dev. Biol.-Animal, 33: 310-314, 1997.
9. 3 analogues and tamoxifen. Cancer Res., 54: 5711-5717, 1994.
10. James, S. Y., Mackay, A. G., Binderup, L., and Colston, K. W. Effects of a new synthetic vitamin D analogue, EB1089, on the oestrogen-responsive growth of human breast cancer cells. J. Endocrinol., 141: 555-563, 1994.
11. Anzano, M. A., Smith, J. M., Uskokovic, M. R., Peer, C. W., Mullen, L. T., Letterio, J. J., Welsh, M. C., Shrader, M. W., Logsdon, D. L., Driver, C. L., Brown, C. C., Roberts, A. B., and Sporn, M. B. 1α,25-Dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24-5531), a new deltanoid (vitamin D analogue) for prevention of breast cancer in the rat. Cancer Res., 54: 1653-1656, 1994.
12. Lown, J. W., Chen, H. H., Plambeck, J. A., and Acton, E. M. Further studies on the generation of reactive oxygen species from activated anthracyclines and the relationship to cytotoxic action and cardiotoxic effects. Biochem. Pharmacol., 31: 575-581, 1982.
13. Myers, C. E., McGuire, W. P., Liss, R. H., Ifrim, I., Grotzinger, K., and Young, R. C. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science (Washington DC), 197: 165-167, 1977.
14. Doroshow, J. H. Anthracycline antibiotic-stimulated superoxide, hydrogen peroxide, and hydroxyl radical production by NADH dehydrogenase. Cancer Res., 43: 4543-4551, 1983.
15. Zwelling, L. A. Topoisomerase II as a target of antileukemia drugs: a review of controversial areas. Hematol. Pathol., 3: 101-112, 1989.
16. Binaschi, M., Capranico, G., De-Isabella, P., Mariani, M., Supino, R., Tinelli, S., and Zunino, F. Comparison of DNA cleavage induced by etoposide and doxorubicin in two human small-cell lung cancer lines with different sensitivities to topoisomerase II inhibitors. Int. J. Cancer, 45: 347-352, 1990.
17. Kasahara, K., Fujiwara, Y., Sugimoto, Y., Nishio, K., Tamura, T., Matsuda, T., and Saijo, N. Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines. J. Natl. Cancer Inst., 84: 113-118, 1992.
18. Camussi, G., Albano, E., Tetta, C., and Bussolino F. The molecular action of tumor necrosis factor α. Eur. J. Biochem., 202: 3-14, 1991.
19. Bergman, M., Cohen, F., Schlesinger, H., and Kessler-Icekson, G. Effects of amiodarone on beating rate and Na-K-ATPase activity in cultured neonatal rat heart myocytes. Gen. Pharmacol., 26: 285-290, 1995.
20. Dujovne, C. A., Shoeman, D., and Bianchine, J. Experimental basis for the different hepatoxicity of erythromycin preparation in man. J. Lab. Clin. Med., 79: 832-844, 1972.
21. Elstner, E. F., and Heupel, A. Inhibition of nitrate formation from hydroxyl ammoniumchloride: a simple assay for superoxide dismutase. Anal. Biochem., 70: 616-620, 1976.
22. Minamide, L. S., and Bamburg, J. R. A filter paper dye-binding assay for quantitative determination of protein without interference from reducing agents or detergents. Anal? Biochem., 190: 66-70, 1990.
23. Chomczynski, P., and Sacchi, N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162: 156-159, 1987.
24. Ngo, E. O., Sun, T. P., Chang, J. Y., Wang, C. C., Chi, K. H., Cheng, A. L., and Nutler, L. M. Menadione-induced DNA damage in a human tumor cell line. Biochem. Pharmacol., 42: 1961-1968, 1991.
25. Schneider, E., Hsiang, Y. H., and Liu, L. F. DNA topoisomerases as anticancer drug targets. Adv. Pharmacol., 21: 149-183, 1990.
26. Singal, P. K., Liskovik, K., Li, T., and Kumar, D. Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J. 11: 931-936, 1997.
27. 3 receptors identified in the rat heart. J. Mol. Cell. Cardiol., 18: 67-72, 1986.
28. Sarvazyan, N. A., Askari, A., and Huang, W. H. Effects of doxorubicin on cardiomyocytes with reduced level of superoxide dismutase. Life Sci., 57: 1003-1010, 1995.
29. Zyad, A., Benard, J., Tursz, T., Clarke, R., and Chouaib, S. Resistance to TNF-α, and Adriamycin in the human breast cancer MCF-7 cell line: relationship to MDRI, MnSOD, and TNF gene expression. Cancer Res., 54: 825-831, 1994.
30. Doroshow, J. H. Prevention of doxorubicin-induced killing of MCF-7 human breast cancer cells by oxygen radical scavengers and iron chelating agents. Biochem. Biophys. Res. Commun., 26: 330-335, 1986.
31. Doroshow, J. H., Akman S., Esworthy, S., Chu, F. F., and Burke, T. Doxorubicin resistance conferred by selective enhancement of intracellular glutathione peroxidase or superoxide dismutase content in human MCF-7 breast cancer cells. Free Radical Res. Commun.. 12-13 Pt 2: 779-781, 1991.
32. Sherman, L., Levanon, D., Lieman-Hurwitz, J., Dafni, N., and Groner, Y. Human Cu/Zn superoxide dismutase gene: molecular characterization of its two mRNA species. Nucleic Acids Res., 12: 9349-9365, 1984.
33. Bustamante, J., Galleano, M., Medrano, E. E., and Boveris, A. Adriamycin effects on hydroperoxide metabolism and growth of human breast tumor cells. Breast Cancer Res. Treat., 17: 145-153, 1990.
34. Gottesman, M. N., and Pastan, I. Biochemistry of multidrug resistance mediated by the multi drug transporter. Annu. Rev. Biochem., 62: 385-427, 1993.
35. Fridovich, I. Superoxide dismulases. Adv. Enzymol. Relat. Areas Mol. Biol., 58: 61-97, 1986.
36. Imlay, J. A., and Linn, S. DNA damage and oxygen radical toxicity. Science (Washington DC), 240: 1302-1309, 1988.
37. Mantovani, A., Bottazzi, B., Colotta, F., Sozzani, S., and Ruco L. The origin and function of tumor-associated macrophages. Immunol. Today, 13: 265-270, 1992.
38. Dusso, A., Finch, J., Delmez, J., Rapp, N., Lopez-Hilker, S., Brown, A., and Slatopolsky, E. Extrarenal production of calcitriol. Kidney Int. 29: S36-S40, 1990.
39. Verweij, J., Funke-Kupper, A. J., Teule, G. J., and Pinedo, H. M. A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C. Med. Oncol. Tumor Pharamacother. 5: 159-163, 1988.
40. Toyokuni, S., Okamoto, K., Yodoi, J., and Hiai, H. Persistent oxidative stress in cancer. FEBS Lett., 358: 1-3, 1995.